About
Medibio (ASX: MEB), is an evidence-based medical technology company that will radically change how mental health care is delivered through objective, data driven assessment & management. Mental health represents the largest clinical problem today with an estimated 350M people world-wide suffering from...
Medibio (ASX: MEB), is an evidence-based medical technology company that will radically change how mental health care is delivered through objective, data driven assessment & management. Mental health represents the largest clinical problem today with an estimated 350M people world-wide suffering from depression. Given the subjective nature of the clinical assessments, less than 10% of patients receive optimal therapy on initial assessment. To address the clinical need, Medibio has developed an analytic platform that utilizes patented (and patent pending) panel of circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. Medibio has a rich portfolio of products to address broad spectrum mental health with strong foundation IP. Medibio’s first product, a depression diagnostic aid, is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd. Medibio Limited (ASX: MEB) was previously named BioProspect Limited (ASX: BPO). The company changed its name on 1 December 2014 as part of a corporate transformation, with new assets, a new Board and new management.

Executive Management :

Mr. Jack Cosentino ( CEO & Managing Director )
Mr. Brian Mower ( Chief Financial Officer )
Mr. Yashar Behzadi ( Chief Product Officer )
Dr. Greg Moon ( Chief Medical Officer )
Mr. Nathan Cowahl ( VP, Algorithm Development & Data Science )

Board of Directors :

Mr. Chris Indermaur ( Chairman )
Mr. Kris Knauer ( Director )
Dr. Franklyn G. Prendergast ( Director )
Mr. Andrew Maxwell ( Director )